Lokivetmab for Dogs and Cats
Vet-reviewed by Dr. Pippa Elliott, BVMS MRCVS ·
What Is Lokivetmab for Dogs and Cats
Overview
Lokivetmab is a canine-specific monoclonal antibody, meaning it’s designed to target one thing only: IL-31, the chemical that causes severe itching in dogs with allergies. Because it is so targeted, it works quickly and causes fewer side effects compared to steroids or other broad immune-suppressing medications.
Cytopoint is used for long-term management of atopic dermatitis and is safe for repeated injections. It is often chosen by veterinarians for dogs who need rapid relief, monthly dosing, or who cannot tolerate steroids, Apoquel®, or cyclosporine. Owners also report high satisfaction due to ease of use and improved pet comfort.
Explore more skin-related medications in our Dermatology section.
What Is Lokivetmab for Dogs and Cats Used For
Lokivetmab works by binding to IL-31, the chemical messenger responsible for itch sensations. When IL-31 is blocked, the dog’s brain stops receiving “itch signals,” so the urge to scratch drops quickly. This reduces skin damage, helps skin heal, and improves comfort—without suppressing the whole immune system.
| Condition | Notes |
|---|---|
| Atopic dermatitis (environmental allergies) | Main FDA-approved use; provides fast itch reduction. |
| Chronic itching | Reduces scratching within 1–2 days after injection. |
| Skin lesions from self-trauma | Helps heal red, irritated, or damaged skin by stopping the itch cycle. |
| Long-term allergy management | Safe for repeated monthly use. |
| Dogs who can't tolerate steroids or immune suppressants | Preferred alternative due to fewer systemic effects. |
Drug Facts
Lokivetmab is a targeted monoclonal antibody injection used to control itching in dogs with atopic dermatitis. It contains no steroids, no cyclosporine, and does not act as a general immunosuppressant. It is given once every 4–8 weeks and is considered very safe, even when used long-term.
Common Brands
Cytopoint® (Zoetis)
Drug Class
Canine monoclonal antibody (anti-IL-31)
Substance Classification
Prescription biological therapy
Generic Status
No generics available
Availability
Prescription
Lokivetmab for Dogs and Cats Dosage Forms
Lokivetmab is supplied as a ready-to-use injectable solution in single-dose vials. It is given as a subcutaneous injection (under the skin). Dosing is based on mg per kg of body weight.
Injection Vials
| Qty/Size | Price as low as | Price per unit |
|---|---|---|
| 10 mg | $72.00 | $72.00 |
| 20 mg | $89.00 | $89.00 |
| 30 mg | $105.00 | $105.00 |
| 40 mg | $125.00 | $125.00 |
Typical Dosing for Lokivetmab for Dogs and Cats
Lokivetmab is given once every 4–8 weeks, depending on the dog’s response. Many dogs receive it monthly for best results. The minimum recommended dose is 1–2 mg/kg, with most studies using 2 mg/kg.
Relief often starts within 1–2 days, with effects lasting at least 1 month.
Subcutaneous Injection
| Group | Typical Dose | Notes |
|---|---|---|
| Dogs (all sizes) | 2 mg/kg every 4–8 weeks | Most dogs receive monthly injections. |
| Dogs with severe itching | 2 mg/kg every 4 weeks | Provides more consistent itch control. |
| Long-term management | Vet-adjusted 1–2 mg/kg | Very safe for repeated use. |
Dogs are usually monitored for 30 minutes after injection to ensure no immediate reaction occurs.
Risks and Warnings for Lokivetmab for Dogs and Cats
Lokivetmab is considered very safe and is generally better tolerated than steroids or immune-modulating allergy drugs. Most reactions, when they occur, are mild and temporary. Long-term studies show excellent safety even with repeated monthly dosing.
Safety Overview
- Mild side effects occurred in ~16% of dogs, similar to placebo.
- No immediate allergic reactions (no wheals or vomiting) were seen after injection.
- Injection discomfort occurred in ~5% of dogs, similar to placebo.
- Long-term studies (12 months) show strong continued safety.
Immunogenicity (Antibody Reaction)
- ~2.5% of dogs developed antibodies against Lokivetmab.
- These rarely affected the medication’s performance.
- No hypersensitivity reactions were linked to these antibodies.
Secondary Skin Infections
- Scratching typically decreases with treatment, reducing bacterial infections.
- Some dogs still developed yeast (Malassezia) infections during therapy.
Overall, Lokivetmab has one of the safest profiles of all canine allergy medications.
Eicosaderm for Dogs Warnings and Precautions
Use Lokivetmab with the following precautions in mind:
- For dogs only do not use in other species.
- Use cautiously in dogs with immune disorders.
- Monitor dogs with a history of yeast infections.
- Always give under veterinary supervision.
- Report persistent vomiting, lethargy, or skin changes to your vet.
- Keep dogs for 30 minutes after injection in case of discomfort.
- Not for home injection—administered only by veterinarians.
Disclaimer: This information is for educational purposes only and should not replace professional veterinary advice. Always consult your veterinarian before using or combining any medications for your pet.
Frequently Asked Questions (FAQ)
How fast does Lokivetmab work?
Most dogs feel relief within
1–2 days
, with itching dropping significantly.
How long does one injection last?
A single injection lasts
4–8 weeks
, depending on the dog.
Is Lokivetmab safer than steroids?
Yes, Lokivetmab targets
only itch
and does
not suppress the whole immune system
, making it safer for long-term use.
Can Lokivetmab be used with other medications?
Yes. Studies show it is safe with antibiotics, antifungals, Apoquel®, and other drugs.
Does Lokivetmab help skin infections?
It reduces scratching, which helps prevent bacterial infections. Yeast infections may still occur and need separate treatment.
Related Medications & Supplements
Dogs receiving Lokivetmab (Cytopoint) for allergies may also benefit from additional medications or supplements that support skin health, reduce inflammation, or manage breakthrough itching. These treatments are commonly used alongside allergy therapies.
- Apoquel – oral anti-itch medication for allergic dermatitis
- Oclacitinib – generic name for Apoquel, controls itch and inflammation
- Fish oil – natural source of anti-inflammatory omega-3 fatty acids
- Omega-3 fatty acids – supports skin barrier health and reduces inflammation
- Animax ointment – topical ointment for localized skin infections or irritation
- Derma-Vet ointment – medicated ointment for inflammatory or infected skin lesions
References
- Gober, M., Amodie, D., Mellencamp, M., Hillier, A., et al. (2025). Long term use of lokivetmab (Cytopoint®) in atopic dogs. BMC Veterinary Research. Available at: https://pubmed.ncbi.nlm.nih.gov/40133889/ (pubmed.ncbi.nlm.nih.gov)
- Krautmann, M., et al. (2023). Laboratory safety evaluation of lokivetmab, a canine anti-IL-31 monoclonal antibody. Veterinary Dermatology. Available at: https://www.sciencedirect.com/science/article/pii/S0165242723000284 (sciencedirect.com)
- Michels, G., Walsh, K., Kryda, K., Mahabir, S., Hoevers, J., & Martinon, O. (2016). A blinded, randomised, placebo-controlled trial of the safety of lokivetmab (ZTS-00103289) in client-owned dogs with atopic dermatitis. Veterinary Dermatology. Available at: https://www.zoetis.cl/cytopoint/pdf/michels-g-et-al.-vet-dermatol-2016.-safe-study.pdf
- Szczepanik, M.P., et al. (2020). Evaluation of the clinical efficiency of lokivetmab in client privately owned atopic dogs - multicenter study. Available at: https://www.cabidigitallibrary.org/doi/pdf/10.5555/20220031770
- Kasper, B., et al. (2024). Long-term use of lokivetmab in dogs with atopic dermatitis. Veterinary Dermatology. Available at: https://onlinelibrary.wiley.com/doi/10.1111/vde.13286
- Campos, M.L., et al. (2021). Prospective Evaluation of the Use of Lokivetmab in Dogs With Atopic Dermatitis in Brazil. Available at: https://www.researchgate.net/publication/355460535_Prospective_Evaluation_of_the_Use_of_Lokivetmab_in_Dogs_With_Atopic_Dermatitis_in_Brazil
- Bruet, V., et al. (2022). Clinical Guidelines for the Use of Antipruritic Drugs in the Control of the Most Frequent Pruritic Skin Diseases in Dogs Veterinary Sciences. Available at: https://www.mdpi.com/2306-7381/9/4/149
Editor
The Webvet Editorial Team is a collective of seasoned pet-care journalists, veterinary content specialists, and industry editors dedicated to delivering accurate, trustworthy, and compassionate pet health information. With decades of combined experience across veterinary reporting, pet wellness education, and consumer product research, our team works closely with veterinarians and certified pet experts to ensure every article is both evidence-based and easy to understand.
Veterinarian · BVMS MRCVS
Dr. Pippa Elliott, BVMS, MRCVS, is a veterinarian with nearly 30 years of experience in companion animal practice. Dr. Elliott earned her Bachelor of Veterinary Medicine and Surgery from the University of Glasgow. She was also designated a Member of the Royal College of Veterinary Surgeons. Married with 2 grown-up kids, Dr. Elliott has a naughty Puggle named Poggle, 3 cats and a bearded dragon.
